Evidence map›Paper›PMID 28000698›Full record

ArticleEuropean journal of human genetics : EJHG2017

Mosaicism and prenatal diagnosis options: insights from retinoblastoma.

Catherine Dehainault, Lisa Golmard, Gaël A Millot, Agathe Charpin, Anthony Laugé, Julien Tarabeux, Isabelle Aerts, Nathalie Cassoux, Dominique Stoppa-Lyonnet, Marion Gauthier-Villars and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Prenatal Diagnosis of Retinoblastomas: A Scoping Review.International journal of general medicine · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Catherine DehainaultService de Génétique, Pôle de Médecine diagnostique et théranostique, Institut Curie, Paris, France.
Lisa GolmardService de Génétique, Pôle de Médecine diagnostique et théranostique, Institut Curie, Paris, France.
Gaël A MillotInstitut Curie, PSL Research University, 26 rue d'Ulm, Paris, France.
Agathe CharpinService de Génétique, Pôle de Médecine diagnostique et théranostique, Institut Curie, Paris, France.
Anthony LaugéService de Génétique, Pôle de Médecine diagnostique et théranostique, Institut Curie, Paris, France.
Julien TarabeuxService de Génétique, Pôle de Médecine diagnostique et théranostique, Institut Curie, Paris, France.
Isabelle AertsDépartement d'oncologie pédiatrique, adolescents jeunes adultes, Institut Curie, Paris, France.
Nathalie CassouxDépartement d'oncologie chirurgicale, service d'Ophtalmologie, Institut Curie, Paris, France.
Dominique Stoppa-LyonnetService de Génétique, Pôle de Médecine diagnostique et théranostique, Institut Curie, Paris, France.
Marion Gauthier-VillarsService de Génétique, Pôle de Médecine diagnostique et théranostique, Institut Curie, Paris, France.
Claude HoudayerService de Génétique, Pôle de Médecine diagnostique et théranostique, Institut Curie, Paris, France.
Institut Curie · FRDélégation Paris 5 · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In sporadic cases, a post-zygotic mutational event signifies a somatic mosaicism in the affected child only, which implies that these mutations affect only a portion of the body. Therefore siblings do not need follow-up. On the other hand, a pre-zygotic mutation transmitted by an unaffected mosaic parent implies recurrent risks in offspring. To better estimate the contribution of pre- and post-zygotic events, we analysed 124 consecutive bilateral retinoblastoma probands, carrying a heterozygous RB1 pathogenic variant and their unaffected, non-carrier parents. In order to evaluate somatic mosaicism in blood, the deleterious RB1 pathogenic variant identified in the proband, was searched for in the unaffected parents, using targeted deep sequencing. Observed recurrences, which represent an estimation of germline and somatic mosaicisms, were recorded and computed in the sibships. Deep sequencing revealed one mosaic-unaffected parent out of 124 tested couples, which provides an estimation of the maximal risk of recurrence, due to parental mosaicism, at 0.4%. Follow-up in the sibships showed one recurrence, providing a maximal recurrence risk, due to parental mosaicism, at 0.8%. Two different statistical strategies led to close estimates (0.4 and 0.8% risks) which appeared 266-533-fold higher, as compared with the general population. These recurrence estimates could be considered when counselling couples with retinoblastoma or diseases with a high de novo mutation rate.

Indexed as

MosaicismGenetic CounselingGenetic TestingGerm-Line MutationHeterozygoteHumansMutation RateParentsPrenatal DiagnosisRetinoblastomaRetinoblastoma Binding ProteinsSiblingsUbiquitin-Protein LigasesRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein Ligases

Identifiers

PMID28000698
PMCPMC5315511
OpenAlexW2564622342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.